MCID: AGG011
MIFTS: 23

Aggressive B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for Aggressive B-Cell Non-Hodgkin Lymphoma:

Name: Aggressive B-Cell Non-Hodgkin Lymphoma 58
Aggressive B-Cell Nhl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA300846

Summaries for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards based summary : Aggressive B-Cell Non-Hodgkin Lymphoma, also known as aggressive b-cell nhl, is related to lymphoma, hodgkin, classic and lymphoma, non-hodgkin, familial. An important gene associated with Aggressive B-Cell Non-Hodgkin Lymphoma is HSPH1 (Heat Shock Protein Family H (Hsp110) Member 1). The drugs Gemcitabine and Pixantrone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone marrow.

Related Diseases for Aggressive B-Cell Non-Hodgkin Lymphoma

Diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 17, show less)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 11.0
2 lymphoma, non-hodgkin, familial 11.0
3 b-cell non-hodgkin lymphoma 11.0
4 b-cell lymphoma 10.8
5 diffuse large b-cell lymphoma 10.7
6 lymphoma 10.7
7 neutropenia 10.7
8 follicular lymphoma 10.6
9 burkitt lymphoma 10.4
10 mantle cell lymphoma 10.4
11 relapsed/refractory diffuse large b-cell lymphoma 10.2
12 primary mediastinal b-cell lymphoma 10.2
13 peripheral nervous system disease 10.2
14 severe combined immunodeficiency 10.2
15 neuropathy 10.2
16 pulmonary embolism 10.2
17 acute graft versus host disease 10.2

Graphical network of the top 20 diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma:



Diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for Aggressive B-Cell Non-Hodgkin Lymphoma

Drugs & Therapeutics for Aggressive B-Cell Non-Hodgkin Lymphoma

Drugs for Aggressive B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 87, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Pixantrone Approved, Investigational Phase 3 144510-96-3
3
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
4
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
5
Allopurinol Approved Phase 3 315-30-0 2094
6
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
7
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
8
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
9
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
10
Lenalidomide Approved Phase 3 191732-72-6 216326
11
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
19
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
20
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
24 Molgramostim Investigational Phase 3 99283-10-0
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Micronutrients Phase 3
27 Vitamins Phase 3
28 Antidotes Phase 3
29 Antioxidants Phase 3
30 Nutrients Phase 3
31 Protective Agents Phase 3
32 Calcium, Dietary Phase 3
33 Trace Elements Phase 3
34 Immunosuppressive Agents Phase 3
35 Anti-Infective Agents Phase 3
36 Antiviral Agents Phase 3
37 Antimetabolites Phase 3
38 Bendamustine Hydrochloride Phase 3
39 Antineoplastic Agents, Hormonal Phase 3
40 Hormones Phase 3
41 Tubulin Modulators Phase 3
42
Liposomal doxorubicin Phase 3 31703
43 Hormone Antagonists Phase 3
44 Anti-Bacterial Agents Phase 3
45 glucocorticoids Phase 3
46 Antibiotics, Antitubercular Phase 3
47 Anti-Inflammatory Agents Phase 3
48 Antimitotic Agents Phase 3
49 Dermatologic Agents Phase 3
50 Gastrointestinal Agents Phase 3
51 Vitamin B Complex Phase 3
52 Folate Phase 3
53 Antiemetics Phase 3
54 Folic Acid Antagonists Phase 3
55 Vitamin B9 Phase 3
56 Methylprednisolone Acetate Phase 3
57
Calcium Nutraceutical Phase 3 7440-70-2 271
58
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
59
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
60
Blinatumomab Approved, Investigational Phase 2 853426-35-4
61
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
62
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
63
nivolumab Approved Phase 2 946414-94-4
64
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
65
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
66
Cortisone Experimental Phase 2 53-06-5 222786
67 Immunologic Factors Phase 1, Phase 2
68 Etoposide phosphate Phase 1, Phase 2
69 Immunoglobulins Phase 2
70 Antibodies Phase 2
71 Immunoglobulins, Intravenous Phase 2
72 Antibodies, Monoclonal Phase 2
73 Podophyllotoxin Phase 2 518-28-5
74 Keratolytic Agents Phase 2
75 Angiogenesis Inhibitors Phase 2
76 Immunoglobulin G Phase 2
77
Carmustine Approved, Investigational Phase 1 154-93-8 2578
78
Melphalan Approved Phase 1 148-82-3 460612 4053
79
Ifosfamide Approved Phase 1 3778-73-2 3690
80
Mesna Approved, Investigational Phase 1 3375-50-6 598
81
Mechlorethamine Approved, Investigational Phase 1 51-75-2 4033
82
Carboplatin Approved Phase 1 41575-94-4 10339178 38904 498142
83
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
84 Alkylating Agents Phase 1
85 Antirheumatic Agents Phase 1
86 Antineoplastic Agents, Immunological Phase 1
87
Isophosphamide mustard Phase 1 0

Interventional clinical trials:

(showing 24, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
2 A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma Completed NCT00000658 Phase 3 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone
3 Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) Recruiting NCT03570892 Phase 3 Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
4 B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Recruiting NCT03206671 Phase 3 Rituximab window;Additional doses of Rituximab;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin hydrochloride;Vindesine Sulfate;Etoposide;Ifosfamide;Methotrexate;Prednisolone;Vincristine
5 Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. Unknown status NCT00385125 Phase 2 Bendamustine;Rituximab
6 A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma Completed NCT02910063 Phase 2 Blinatumomab
7 Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab Completed NCT00726700 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation Completed NCT02340936 Phase 1, Phase 2 LR-ESHAP (lenalidomide 5 mg);LR-ESHAP (lenalidomide 10 mg);LR-ESHAP (lenalidomide 15 mg);LR-ESHAP (lenalidomide 20 mg)
9 A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) Recruiting NCT03483103 Phase 2
10 A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies Recruiting NCT03484702 Phase 2 JCAR017
11 A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Recruiting NCT03749018 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate
12 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Recruiting NCT03744676 Phase 2
13 A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas Recruiting NCT02747732 Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
14 Phase II Trial of Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Recruiting NCT04094142 Phase 2 Acalabrutinib
15 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
16 An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting NCT03310619 Phase 1, Phase 2 Durvalumab;CC-122;Ibrutinib;CC-220
17 A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL Terminated NCT00180895 Phase 2 Rituximab
18 A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia Recruiting NCT03103971 Phase 1 Cyclophosphamide;Fludarabine
19 Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies Recruiting NCT04088890 Phase 1 Fludarabine;Cyclophosphamide;CD22 CAR
20 A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma Active, not recruiting NCT01840566 Phase 1 Carmustine;Etoposide;Cytarabine;Melphalan
21 A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Terminated NCT02702141 Phase 1 SGN-CD19B
22 (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL Terminated NCT01300793 Phase 1 Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
23 Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant Completed NCT02992223
24 DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas Recruiting NCT02633111

Search NIH Clinical Center for Aggressive B-Cell Non-Hodgkin Lymphoma

Genetic Tests for Aggressive B-Cell Non-Hodgkin Lymphoma

Anatomical Context for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards organs/tissues related to Aggressive B-Cell Non-Hodgkin Lymphoma:

40
B Cells, T Cells, Bone Marrow, Bone, Spleen, Ovary, Appendix

Publications for Aggressive B-Cell Non-Hodgkin Lymphoma

Articles related to Aggressive B-Cell Non-Hodgkin Lymphoma:

(showing 150, show less)
# Title Authors PMID Year
1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. 61
31868632 2020
2
Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. 61
32550718 2020
3
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. 61
32141616 2020
4
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
32546071 2020
5
Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy. 61
31425376 2020
6
Novel agents for mantle cell lymphoma: molecular rational and clinical data. 61
32321318 2020
7
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 61
31997425 2020
8
Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not? 61
32304874 2020
9
Aggressive B-Cell Lymphoma Involving the Appendix and Bilateral Ovaries in an 11-Year-Old Girl. 61
32304857 2020
10
Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. 61
31902733 2020
11
Antiproliferative and proapoptotic effects of Inula viscosa extract on Burkitt lymphoma cell line. 61
32013807 2020
12
MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway. 61
32055277 2020
13
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. 61
31568564 2020
14
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). 61
31879945 2020
15
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. 61
31446199 2019
16
Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. 61
31441943 2019
17
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. 61
31342797 2019
18
Pixantrone beyond monotherapy: a review. 61
31312929 2019
19
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. 61
30696305 2019
20
Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. 61
31069789 2019
21
The acceleration of CAR-T therapy in non-Hodgkin lymphoma. 61
30427551 2019
22
Intussusception in children: lessons learned from intestinal lymphoma as a rare lead-point. 61
31139892 2019
23
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. 61
31262783 2019
24
Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. 61
30702000 2019
25
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. 61
30782611 2019
26
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. 61
31043832 2019
27
Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report. 61
30987612 2019
28
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. 61
30919158 2019
29
CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. 61
30557517 2019
30
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. 61
30280924 2019
31
Management of adults with Burkitt lymphoma. 61
30843890 2018
32
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 61
30166257 2018
33
High-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop. 61
30510878 2018
34
Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. 61
29460043 2018
35
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
28677896 2018
36
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. 61
29577608 2018
37
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. 61
29774105 2018
38
Does maintenance therapy have a role in mantle cell lymphoma treatment? 61
29521148 2018
39
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. 61
29196080 2018
40
Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression. 61
29407771 2018
41
Burkitt's lymphoma with placental invasion diagnosed at cesarean delivery: a case report. 61
29415774 2018
42
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. 61
30020951 2018
43
The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas. 61
29868471 2018
44
Clinical characteristics and survival outcome of primary effusion lymphoma: A review of 105 patients. 61
27859456 2017
45
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. 61
28870643 2017
46
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. 61
29222274 2017
47
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. 61
28485023 2017
48
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop. 61
28140709 2017
49
L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients. 61
28194058 2017
50
Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis. 61
29285019 2017
51
Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. 61
28321348 2017
52
Unusual multiple metastatic localisations in adult Burkitt's lymphoma. A case report. 61
27981287 2016
53
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. 61
27757832 2016
54
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. 61
27376362 2016
55
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. 61
27118109 2016
56
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma. 61
26857688 2016
57
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. 61
27093976 2016
58
Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. 61
26463529 2016
59
Sporadic Burkitt's lymphoma/acute B-cell leukaemia presenting with progressive proptosis and orbital mass in a child. 61
27006106 2016
60
Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report. 61
27408385 2016
61
Clinical Management Updates in Mantle Cell Lymphoma. 61
27083466 2016
62
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr. 61
26657116 2016
63
Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform. 61
26660439 2016
64
Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. 61
25926064 2016
65
[Burkitt lymphoma, a diagnostic emergency] 61
30512408 2016
66
PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas. 61
26549638 2016
67
Clinical association of baseline levels of conjugated dienes in low-density lipoprotein and nitric oxide with aggressive B-cell non-Hodgkin lymphoma and their relationship with immunoglobulins and Th1-to-Th2 ratio. 61
27330333 2016
68
Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran. 61
27039799 2016
69
Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. 61
26643319 2015
70
Correction: Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. 61
26567366 2015
71
The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells. 61
26116769 2015
72
Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray. 61
26281838 2015
73
Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. 61
25492700 2015
74
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. 61
25573990 2015
75
Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. 61
25488969 2015
76
Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene. 61
25623859 2015
77
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. 61
25395425 2015
78
Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop. 61
25944379 2015
79
How I treat Burkitt lymphoma in adults. 61
25258344 2014
80
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. 61
25039868 2014
81
Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop. 61
24512319 2014
82
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. 61
25228589 2014
83
[Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype]. 61
25511487 2014
84
Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. 61
24722703 2014
85
HIV associated Burkitt's lymphoma. 61
25856946 2014
86
MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. 61
24843176 2014
87
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. 61
24578014 2014
88
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. 61
24633940 2014
89
Detection of B-cell populations with monotypic light chain expression in cerebrospinal fluid specimens from patients with multiple sclerosis by polychromatic flow cytometry. 61
23818243 2014
90
Diffuse large B-cell lymphoma-treatment approaches in the molecular era. 61
24217204 2014
91
How I treat nodular lymphocyte predominant Hodgkin lymphoma. 61
24215035 2013
92
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. 61
23795711 2013
93
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. 61
23652586 2013
94
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. 61
23797978 2013
95
A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. 61
24070462 2013
96
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. 61
22833464 2013
97
Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization. 61
23110670 2013
98
Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma. 61
22476761 2012
99
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. 61
22968454 2012
100
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. 61
23062193 2012
101
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. 61
22180164 2012
102
Radioimmunotherapy for B-cell non-hodgkin lymphomas. 61
22710895 2012
103
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. 61
22374334 2012
104
Burkitt's lymphoma. 61
22333947 2012
105
Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. 61
21612383 2011
106
Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. 61
21498532 2011
107
Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. 61
21292303 2011
108
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. 61
21291867 2011
109
African Burkitt lymphoma: age-specific risk and correlations with malaria biomarkers. 61
21363976 2011
110
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. 61
19756371 2011
111
Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. 61
21286373 2011
112
An update on the management of peripheral T-cell lymphoma and emerging treatment options. 61
22287871 2011
113
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. 61
21133727 2011
114
Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. 61
21473291 2011
115
Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. 61
20799079 2010
116
VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. 61
19926148 2010
117
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. 61
20583964 2010
118
Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. 61
20216076 2010
119
Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. 61
19693502 2010
120
Human Immunodeficiency Virus-associated anaplastic large cell lymphoma. 61
20141444 2010
121
Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. 61
19776000 2009
122
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. 61
19536846 2009
123
[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. 61
20021946 2009
124
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. 61
19669190 2009
125
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. 61
19225536 2009
126
Ten years of rituximab in NHL. 61
19243307 2009
127
High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. 61
18842613 2009
128
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 61
18833583 2008
129
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. 61
18569635 2008
130
Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. 61
17943285 2008
131
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. 61
17971487 2008
132
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
17621406 2007
133
Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas. 61
17303500 2007
134
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. 61
16982464 2006
135
Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 61
16831024 2006
136
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 61
16706552 2006
137
[Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. 61
16351785 2005
138
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. 61
16236611 2005
139
Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma. 61
15642390 2005
140
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. 61
15548997 2004
141
Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas. 61
12960694 2003
142
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 61
12662126 2003
143
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. 61
12406079 2002
144
Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. 61
12040530 2002
145
Autologous and allogeneic transplantation for aggressive NHL. 61
12194719 2002
146
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. 61
11208830 2001
147
T cell rich B cell lymphoma (TCRBCL): study of sixteen cases with review of literature. 61
10420680 1999
148
Fluorescence in situ hybridization assessment of the telomeric regions of jumping translocations in a case of aggressive B-cell non-Hodgkin lymphoma. 61
9309114 1997
149
Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. 61
7751877 1995
150
Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. 61
8380252 1993

Variations for Aggressive B-Cell Non-Hodgkin Lymphoma

Expression for Aggressive B-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for Aggressive B-Cell Non-Hodgkin Lymphoma.

Pathways for Aggressive B-Cell Non-Hodgkin Lymphoma

GO Terms for Aggressive B-Cell Non-Hodgkin Lymphoma

Sources for Aggressive B-Cell Non-Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....